These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Emergent operation for percutaneous coronary rupture after abciximab administration. Roberts CS; Bocanegra NR Ann Thorac Surg; 2001 Jun; 71(6):2024-6. PubMed ID: 11426792 [TBL] [Abstract][Full Text] [Related]
26. A risk-benefit assessment of abciximab in angioplasty. Kleiman NS Drug Saf; 1999 Jan; 20(1):43-57. PubMed ID: 9935276 [TBL] [Abstract][Full Text] [Related]
27. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Kereiakes DJ; Berkowitz SD; Lincoff AM; Tcheng JE; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf RM; Topol EJ Am Heart J; 2000 Jul; 140(1):74-80. PubMed ID: 10874266 [TBL] [Abstract][Full Text] [Related]
28. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Moliterno DJ; Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351 [TBL] [Abstract][Full Text] [Related]
29. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS. Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML; Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544 [TBL] [Abstract][Full Text] [Related]
30. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. Sane DC; Damaraju LV; Topol EJ; Cabot CF; Mascelli MA; Harrington RA; Simoons ML; Califf RM J Am Coll Cardiol; 2000 Jul; 36(1):75-83. PubMed ID: 10898416 [TBL] [Abstract][Full Text] [Related]
31. Profound thrombocytopenia caused by abciximab infusion following. Daley B; Miranda D; Kalra A; Pease D Minn Med; 2014 Oct; 97(10):48-9. PubMed ID: 25651641 [No Abstract] [Full Text] [Related]
32. Comparison of eptifibatide and abciximab with decision analysis. Wong DH Am J Health Syst Pharm; 2001 Aug; 58(15):1432-6. PubMed ID: 11494790 [No Abstract] [Full Text] [Related]
33. Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices. Assali AR; Sdringola S; Moustapha A; Ghani M; Salloum J; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR Catheter Cardiovasc Interv; 2003 Jan; 58(1):1-5. PubMed ID: 12508187 [TBL] [Abstract][Full Text] [Related]
34. Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions. Kleiman NS; Grazeiadei N; Maresh K; Taylor RJ; Frederick B; Lance ET; Effron MB; Jordan RE; Mascelli MA Am Heart J; 2000 Sep; 140(3):492-501. PubMed ID: 10966553 [TBL] [Abstract][Full Text] [Related]
35. Glycoprotein IIb/IIIa inhibitors, surgery and bleeding. Aylward P Aust N Z J Med; 1998 Oct; 28(5):583-4. PubMed ID: 9847944 [No Abstract] [Full Text] [Related]
36. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab. Qureshi AI; Suri MF; Ali Z; Kim SH; Lanzino G; Fessler RD; Ringer AJ; Guterman LR; Hopkins LN Neurosurgery; 2002 Mar; 50(3):466-73; discussion 473-5. PubMed ID: 11841713 [TBL] [Abstract][Full Text] [Related]
37. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Topol EJ; Mark DB; Lincoff AM; Cohen E; Burton J; Kleiman N; Talley D; Sapp S; Booth J; Cabot CF; Anderson KM; Califf RM Lancet; 1999 Dec; 354(9195):2019-24. PubMed ID: 10636365 [TBL] [Abstract][Full Text] [Related]
38. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab. Nguyen N; Salib H; Mascarenhas DA J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690 [TBL] [Abstract][Full Text] [Related]
39. Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen. Rinfret S; Kennedy WA; Lachaine J; Lemay A; Rodés-Cabau J; Cohen DJ; Costerousse O; Bertrand OF JACC Cardiovasc Interv; 2010 Oct; 3(10):1011-9. PubMed ID: 20965458 [TBL] [Abstract][Full Text] [Related]
40. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization. Ibbotson T; McGavin JK; Goa KL Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]